Literature DB >> 10854363

Factors associated with severe manifestations of histoplasmosis in AIDS.

L J Wheat1, P Chetchotisakd, B Williams, P Connolly, K Shutt, R Hajjeh.   

Abstract

We report factors associated with severe manifestations of histoplasmosis (such as shock, respiratory failure, and death) in patients with AIDS during an outbreak. Severe disease was present in 28 of 155 patients (17.9%). The following factors were associated with severe disease: black race (odds ratio [OR], 2.8; 95% confidence interval [CI], 1.2-6.2); hemoglobin level <9.5 g/dL (OR, 2.7; 95% CI, 1.2-6.4), partial thromboplastin time >45 s (OR, 3.1; 95% CI, 1.1-9.3); alkaline phosphatase level >2.5 times normal (OR, 3.4; 95% CI, 1.3-8.7); aspartate aminotransferase level >2.5 times normal (OR, 4.2; 95% CI, 1.7-10.0); bilirubin level concentration >1.5 mg/dL (OR, 9.2; 95% CI, 2.5-34.3); creatinine concentration >2.1 mg/dL (OR, 8.3; 95% CI, 2.2-31.9); and albumin concentration <3.5 g/dL (OR, 4.6; 95% CI, 1.3-16.4). Zidovudine use was associated with decreased risk of severe disease (OR, 0.3; 95% CI, 0.1-0.7). Multivariate analysis showed that a creatinine value >2.1 mg/dL (OR, 9.5; 95% CI, 1.7-52) and an albumin value <3.5 g/dL (OR, 4.8; 95% CI, 1.0-22) were associated with an increased risk of severe disease, and zidovudine therapy remained associated with a decreased risk (OR, 0.2; 95% CI, 0.1-0.6). Findings associated with severe histoplasmosis should be recognized early and the cases managed aggressively.

Entities:  

Mesh:

Year:  2000        PMID: 10854363     DOI: 10.1086/313824

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras.

Authors:  Vincent Peigne; Françoise Dromer; Caroline Elie; Olivier Lidove; Olivier Lortholary
Journal:  Am J Trop Med Hyg       Date:  2011-11       Impact factor: 2.345

Review 2.  Bioterrorism and the Role of the Clinical Microbiology Laboratory.

Authors:  Elizabeth Wagar
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

3.  Histoplasmosis in HIV-Infected Patients: Epidemiological, Clinical and Necropsy Data from a Brazilian Teaching Hospital.

Authors:  Alessandro Henrique Damasceno-Escoura; Delio José Mora; Anderson Clayton Cardeal; Júlio Cesar Berto-Nascimento; Renata Margarida Etchebehere; Antônio Carlos Oliveira de Meneses; Sheila Jorge Adad; Adilha Misson Rua Micheletti; Mario León Silva-Vergara
Journal:  Mycopathologia       Date:  2020-02-20       Impact factor: 2.574

Review 4.  Revisiting old friends: Developments in understanding Histoplasma capsulatum pathogenesis.

Authors:  Jon P Woods
Journal:  J Microbiol       Date:  2016-02-27       Impact factor: 3.422

5.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

6.  Clinical and Laboratory Profile of Persons Living with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome and Histoplasmosis from a Colombian Hospital.

Authors:  Diego H Caceres; Angela M Tobón; Angela Ahlquist Cleveland; Christina M Scheel; Dedsy Y Berbesi; Jesús Ochoa; Angela Restrepo; Mary E Brandt; Tom Chiller; Beatriz L Gómez
Journal:  Am J Trop Med Hyg       Date:  2016-08-01       Impact factor: 2.345

7.  Progressive disseminated histoplasmosis in children living with HIV: a case series study.

Authors:  Miguel García-Boyano; Greta Miño-León; William Vega; Luis Prieto; Nelly Chávez-Solórzano; Dalton Solís Montiel
Journal:  Eur J Pediatr       Date:  2021-02-08       Impact factor: 3.183

8.  Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum.

Authors:  Joshua D Nosanchuk; Judith N Steenbergen; Li Shi; George S Deepe; Arturo Casadevall
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

9.  A monoclonal antibody to Histoplasma capsulatum alters the intracellular fate of the fungus in murine macrophages.

Authors:  Li Shi; Priscila C Albuquerque; Eszter Lazar-Molnar; Xintao Wang; Laura Santambrogio; Attila Gácser; Joshua D Nosanchuk
Journal:  Eukaryot Cell       Date:  2008-05-16

10.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.